Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 315

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 315
---
 CHF 0.80 and issued to the holders Pre -FundedWarrants to purchase up to 136,648 common shares, or the Pre -FundedWarrants. Each Pre -FundedWarrant is exercisable for one common share at an exercise price of CHF 0.80 per share. The Pre -FundedWarrants are immediately exercisable and may be exercised at any time until all of the Pre -FundedWarrants are exercised in full. On October 10, 2024, we successfully implemented a restructuring measure by converting the claims of related party debt holders in the amount of $2,788,650 into 493,986 common shares. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the debt holders. On December4, 2024, we entered into the PIPE SPA with a certain accredited investor. Pursuant to the terms of the PIPE SPA, the Company agreed to issue and sell to the investor, in a private placement offering, or the Offering, up to 322,580 NLS Common Shares only at a purchase price of $3.10 per Common Share for aggregate gross proceeds of up to $1million, subject to shareholder approval. The initial closing of the Offering in the amount of $500,000 in January 2025, and the subsequent closing of $500,000 may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the Common Shares trading for at least ten consecutive trading days above the purchase price of $3.10, which corresponds to an approximate 15% premium. The Offering is expected to result in gross proceeds to the Company of up to $1million. The Company intends to further use the net proceeds from the Offering for working capital and general corporate purposes. 169 On March27, 2025, we entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122 Preferred Shares with a conversion price of $1.65 per share, for aggregate gross proceeds of $2million. Pursuant to the terms of the March 2025 SPA, the investors may purchase up to $1million of additional Preferred Shares on identical terms as the initial closing, subject to the Company